Triumeq vs. Biktarvy

• Are Triumeq and Biktarvy the Same Thing?
• What Are Possible Side Effects of Triumeq?
• What Are Possible Side Effects of Biktarvy?
• What Is Triumeq?
• What Is Biktarvy?
• What Drugs Interact With Triumeq?
• What Drugs Interact With Biktarvy?
• How Should Triumeq be Taken?
• How Should Biktarvy be Taken?

Triumeq (abacavir, dolutegravir, and lamivudine) and Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) are combinations of an integrase strand transfer inhibitor (INSTI) and two HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs) used to treat human immunodeficiency virus type 1 (HIV1) infection.

Side effects of Triumeq and Biktarvy that are similar include insomnia, headache, fatigue, diarrhea, nausea, nightmares or abnormal dreams, and dizziness.

Side effects of Triumeq that are different from Biktarvy include vomiting, fever, loss of appetite, low energy, abnormal body fat distribution, numbness and tingling, hypersensitivity reactions (fever, rash, shortness of breath, cough, or sore throat), joint pain or swelling, muscle pain, extremity swelling, depression, and spinning sensation (vertigo).

Both Triumeq and Biktarvy may interact with other medicines to treat HIV or AIDS, dofetilide, antacids or laxatives that contain aluminum or magnesium (Maalox, Milk of Magnesia, Mylanta, Pepcid Complete, Rolaids, and others), vitamin or mineral supplements that contain calcium or iron, St. John's wort, and medicines that contain metformin.

Triumeq may also interact with sucralfate, buffered medicines, and dalfampridine.

Biktarvy may also interact with anticonvulsants, antimycobacterials, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple nonsteroidal anti-inflammatory drugs (NSAIDs).

Common side effects of Triumeq include:

• insomnia,
• headache,
• fatigue,
• diarrhea,
• nausea,
• vomiting,
• fever,
• loss of appetite,
• low energy,
• nightmares or abnormal dreams,
• abnormal body fat distribution,
• numbness and tingling,
• hypersensitivity reactions (fever, rash, shortness of breath, cough, or sore throat),
• joint pain or swelling,
• muscle pain,
• extremity swelling,
• depression,
• dizziness, and
• spinning sensation (vertigo).

Common side effects of Biktarvy include:

• diarrhea,
• nausea,
• headache,
• fatigue,
• abnormal dreams,
• dizziness, and
• insomnia

Triumeq may interact with dofetilide and other drugs. Tell your doctor all medications and supplements you use.

Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) is a three-drug combination of a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and two HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy.

Triumeq may interact with dexamethasone, imatinib, isoniazid, nefazodone, St. John's wort, antibiotics, antifungals, barbiturates, heart or blood pressure medications, HIV/AIDS medicines, medicines to treat narcolepsy, medications to treat osteoporosis or Paget's disease of bone, seizure medications, or grapefruit and grapefruit juice. Tell your doctor all medications and supplements you use.

Biktarvy may interact with other antiretroviral medications, dofetilide, anticonvulsants, antimycobacterials, St John's wort, antacids containing aluminum or magnesium, supplements containing calcium or iron, metformin, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple nonsteroidal anti-inflammatory drugs (NSAIDs). Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Biktarvy; it is unknown how it would affect a fetus. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Biktarvy during pregnancy. Because of the potential for HIV transmission, breastfeeding while using Biktarvy is not recommended.

The adult dose of Triumeq is one tablet daily.

Biktarvy is a three-drug fixed dose combination product containing 50 mg of bictegravir (BIC), 200 mg of emtricitabine (FTC), and 25 mg of tenofovir alafenamide (TAF). The recommended dosage of Biktarvy is one tablet taken once daily with or without food.